Clinical Trial Update: Bioequivalence Study of Sorafenib Tablet and Nexavar [Phase 1]

View source ↗

Summary

A Phase 1 bioequivalence study comparing sorafenib tablet to Nexavar under fasting conditions has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Differentiated Thyroid Carcinoma
• Hepatocellular Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)
• Sorafenib tablet (generic) (sorafenib)

Snippet

Sponsor: Yabao Pharmaceutical Group | Conditions: Fasting | Phase 1 | Status: COMPLETED